immunotherapy

News

Lilly has signed a deal with CureVac to develop up to five next-generation cancer vaccines which use messenger RNA (mRNA) technology.

News

Opdivo performed better than BMS' Yervoy in clinical trial.

News

BMS is looking to get ahead of its rival Merck & Co. by overcoming resistance to PD-1 immunotherapy in triple negative breast cancer patients.

Views & Analysis

Robert Iannone, AstraZeneca's head of immune-oncology research, on the unpredictable immunotherapy market.

Events

Partner Content

Develop More Clinically Impactful ICI Therapeutics

Events

Partner Content

Join the Exploding Neoantigen Therapeutics Community